Additional information
| Trade Name | Spexib |
|---|---|
| Generic Name | Centrinib |
| Manufacturer | Novartis India Ltd |
| Drug Type | Oncology |
| Indication | Lung Cancer |
| Doasage Form | Capsules |
| Packaging | 3 X 50 Capsules |
SPEXIB (Ceritinib)-150 mg
SPEXIB (Ceritinib) is a targeted therapy that targets and binds to the tyrosine kinase receptors and inhibits ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1on the surface of the cell. By binding to these receptors ceritinib blocks an important pathway that promotes cell division.
Ceritinib is used to treat metastatic non-small cell lung cancer (NSCLC). Lung cancers whose tumors that have a certain type of abnormal anaplastic lymphoma kinase “ALK” gene.
